A second phase III trial to investigate the efficacy of lasofoxifene for the treatment of vulvovaginal atrophy in postmenopausal women

Trial Profile

A second phase III trial to investigate the efficacy of lasofoxifene for the treatment of vulvovaginal atrophy in postmenopausal women

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2016

At a glance

  • Drugs Lasofoxifene (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Acronyms GARNET
  • Most Recent Events

    • 10 Feb 2016 Results from this trial will be presented at the annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), according to a Sermonix Pharmaceuticals media release.
    • 05 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top